Titre : Maladie du greffon contre l'hôte

Maladie du greffon contre l'hôte : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cloud Computing
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Maladie du greffon contre l'hôte : Questions médicales les plus fréquentes", "headline": "Maladie du greffon contre l'hôte : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Maladie du greffon contre l'hôte : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-17", "dateModified": "2025-05-12", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Maladie du greffon contre l'hôte" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Maladies du système immunitaire", "url": "https://questionsmedicales.fr/mesh/D007154", "about": { "@type": "MedicalCondition", "name": "Maladies du système immunitaire", "code": { "@type": "MedicalCode", "code": "D007154", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Syndrome de bronchiolite oblitérante", "alternateName": "Bronchiolitis Obliterans Syndrome", "url": "https://questionsmedicales.fr/mesh/D000092122", "about": { "@type": "MedicalCondition", "name": "Syndrome de bronchiolite oblitérante", "code": { "@type": "MedicalCode", "code": "D000092122", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20.452.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Maladie du greffon contre l'hôte", "alternateName": "Graft vs Host Disease", "code": { "@type": "MedicalCode", "code": "D006086", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Stephanie J Lee", "url": "https://questionsmedicales.fr/author/Stephanie%20J%20Lee", "affiliation": { "@type": "Organization", "name": "Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington." } }, { "@type": "Person", "name": "Betty K Hamilton", "url": "https://questionsmedicales.fr/author/Betty%20K%20Hamilton", "affiliation": { "@type": "Organization", "name": "Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States of America." } }, { "@type": "Person", "name": "Najla El Jurdi", "url": "https://questionsmedicales.fr/author/Najla%20El%20Jurdi", "affiliation": { "@type": "Organization", "name": "Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis." } }, { "@type": "Person", "name": "Steven Z Pavletic", "url": "https://questionsmedicales.fr/author/Steven%20Z%20Pavletic", "affiliation": { "@type": "Organization", "name": "National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, United States of America." } }, { "@type": "Person", "name": "Anthony D Sung", "url": "https://questionsmedicales.fr/author/Anthony%20D%20Sung", "affiliation": { "@type": "Organization", "name": "Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Neural Networks based Smart e-Health Application for the Prediction of Tuberculosis using Serverless Computing.", "datePublished": "2024-02-20", "url": "https://questionsmedicales.fr/article/38376974", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1109/JBHI.2024.3367736" } }, { "@type": "ScholarlyArticle", "name": "Unicuspid aortic valve by cardiac computed tomography: the best view is from the mountaintop-a case report.", "datePublished": "2024-02-19", "url": "https://questionsmedicales.fr/article/38454958", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1093/ehjcr/ytae097" } }, { "@type": "ScholarlyArticle", "name": "When all computers shut down: the clinical impact of a major cyber-attack on a general hospital.", "datePublished": "2024-02-16", "url": "https://questionsmedicales.fr/article/38433989", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fdgth.2024.1321485" } }, { "@type": "ScholarlyArticle", "name": "Simultaneously improving accuracy and computational cost under parametric constraints in materials property prediction tasks.", "datePublished": "2024-02-16", "url": "https://questionsmedicales.fr/article/38365691", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13321-024-00811-6" } }, { "@type": "ScholarlyArticle", "name": "Computational redesign of a hydrolase for nearly complete PET depolymerization at industrially relevant high-solids loading.", "datePublished": "2024-02-15", "url": "https://questionsmedicales.fr/article/38360963", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41467-024-45662-9" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système immunitaire", "item": "https://questionsmedicales.fr/mesh/D007154" }, { "@type": "ListItem", "position": 3, "name": "Maladie du greffon contre l'hôte", "item": "https://questionsmedicales.fr/mesh/D006086" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Maladie du greffon contre l'hôte - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Maladie du greffon contre l'hôte", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Maladie du greffon contre l'hôte", "description": "Comment diagnostiquer la GVHD ?\nQuels tests sont utilisés pour la GVHD ?\nQuels signes cliniques indiquent la GVHD ?\nLa GVHD peut-elle être confondue avec d'autres maladies ?\nQuel rôle joue l'historique médical dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Cloud+Computing&page=995#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Maladie du greffon contre l'hôte", "description": "Quels sont les symptômes cutanés de la GVHD ?\nLa GVHD affecte-t-elle le système digestif ?\nQuels symptômes hépatiques sont associés à la GVHD ?\nLa GVHD peut-elle causer des problèmes oculaires ?\nQuels symptômes respiratoires peuvent survenir ?", "url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Cloud+Computing&page=995#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Maladie du greffon contre l'hôte", "description": "Comment prévenir la GVHD après une greffe ?\nLe choix du donneur influence-t-il la GVHD ?\nLes traitements préventifs sont-ils efficaces ?\nLes greffes de cellules souches de sang de cordon sont-elles plus sûres ?\nLes soins post-greffe aident-ils à prévenir la GVHD ?", "url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Cloud+Computing&page=995#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Maladie du greffon contre l'hôte", "description": "Quels traitements sont utilisés pour la GVHD ?\nLa photothérapie est-elle efficace contre la GVHD ?\nLes greffes de cellules souches peuvent-elles aider ?\nQuels médicaments sont prescrits pour la GVHD ?\nLa thérapie cellulaire est-elle une option ?", "url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Cloud+Computing&page=995#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Maladie du greffon contre l'hôte", "description": "Quelles sont les complications de la GVHD ?\nLa GVHD peut-elle entraîner des infections ?\nQuels cancers peuvent survenir après la GVHD ?\nLa GVHD peut-elle affecter la qualité de vie ?\nComment gérer les complications de la GVHD ?", "url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Cloud+Computing&page=995#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Maladie du greffon contre l'hôte", "description": "Quels sont les principaux facteurs de risque de la GVHD ?\nL'âge influence-t-il le risque de GVHD ?\nLe sexe du receveur joue-t-il un rôle ?\nLes antécédents médicaux augmentent-ils le risque ?\nLa source de greffe influence-t-elle le risque ?", "url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Cloud+Computing&page=995#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la GVHD ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et des biopsies cutanées ou intestinales." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour la GVHD ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des biopsies sont effectués pour évaluer l'atteinte des organes." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent la GVHD ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent éruptions cutanées, diarrhée, et atteinte hépatique." } }, { "@type": "Question", "name": "La GVHD peut-elle être confondue avec d'autres maladies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être confondue avec des infections ou d'autres maladies auto-immunes." } }, { "@type": "Question", "name": "Quel rôle joue l'historique médical dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'historique de greffe et les traitements antérieurs sont cruciaux pour le diagnostic." } }, { "@type": "Question", "name": "Quels sont les symptômes cutanés de la GVHD ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des éruptions, des démangeaisons et des desquamations." } }, { "@type": "Question", "name": "La GVHD affecte-t-elle le système digestif ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des diarrhées, des douleurs abdominales et des nausées." } }, { "@type": "Question", "name": "Quels symptômes hépatiques sont associés à la GVHD ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent jaunisse, fatigue et élévation des enzymes hépatiques." } }, { "@type": "Question", "name": "La GVHD peut-elle causer des problèmes oculaires ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner sécheresse oculaire et inflammation conjonctivale." } }, { "@type": "Question", "name": "Quels symptômes respiratoires peuvent survenir ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la toux, l'essoufflement et des infections pulmonaires peuvent apparaître." } }, { "@type": "Question", "name": "Comment prévenir la GVHD après une greffe ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut l'utilisation d'immunosuppresseurs et le choix de donneurs compatibles." } }, { "@type": "Question", "name": "Le choix du donneur influence-t-il la GVHD ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un donneur HLA compatible réduit le risque de GVHD." } }, { "@type": "Question", "name": "Les traitements préventifs sont-ils efficaces ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements préventifs diminuent significativement l'incidence de la GVHD." } }, { "@type": "Question", "name": "Les greffes de cellules souches de sang de cordon sont-elles plus sûres ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent présenter un risque réduit de GVHD par rapport aux greffes de moelle osseuse." } }, { "@type": "Question", "name": "Les soins post-greffe aident-ils à prévenir la GVHD ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi médical rigoureux et des soins appropriés sont essentiels." } }, { "@type": "Question", "name": "Quels traitements sont utilisés pour la GVHD ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des corticostéroïdes et des immunosuppresseurs." } }, { "@type": "Question", "name": "La photothérapie est-elle efficace contre la GVHD ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la photothérapie peut être utilisée pour traiter les éruptions cutanées." } }, { "@type": "Question", "name": "Les greffes de cellules souches peuvent-elles aider ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des greffes supplémentaires peuvent être envisagées dans certains cas de GVHD sévère." } }, { "@type": "Question", "name": "Quels médicaments sont prescrits pour la GVHD ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme le méthotrexate et la ciclosporine sont souvent prescrits." } }, { "@type": "Question", "name": "La thérapie cellulaire est-elle une option ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie cellulaire peut être explorée pour des cas réfractaires." } }, { "@type": "Question", "name": "Quelles sont les complications de la GVHD ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent infections, défaillance d'organes et cancers secondaires." } }, { "@type": "Question", "name": "La GVHD peut-elle entraîner des infections ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la GVHD affaiblit le système immunitaire, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quels cancers peuvent survenir après la GVHD ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des cancers comme le lymphome et le carcinome peuvent se développer après la GVHD." } }, { "@type": "Question", "name": "La GVHD peut-elle affecter la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes et complications peuvent gravement impacter la qualité de vie." } }, { "@type": "Question", "name": "Comment gérer les complications de la GVHD ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut un suivi médical régulier et des traitements symptomatiques." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque de la GVHD ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, le sexe, et la compatibilité HLA entre donneur et receveur." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de GVHD ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients plus âgés ont un risque accru de développer la GVHD." } }, { "@type": "Question", "name": "Le sexe du receveur joue-t-il un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les hommes peuvent avoir un risque plus élevé de GVHD que les femmes." } }, { "@type": "Question", "name": "Les antécédents médicaux augmentent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies auto-immunes ou de greffes augmentent le risque." } }, { "@type": "Question", "name": "La source de greffe influence-t-elle le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les greffes de moelle osseuse présentent un risque plus élevé que celles de sang de cordon." } } ] } ] }

Sources (10000 au total)

Unicuspid aortic valve by cardiac computed tomography: the best view is from the mountaintop-a case report.

Unicuspid aortic valve (UAV) is a rare valvular heart disease and a challenging diagnosis. Advanced imaging techniques, particularly cardiac computed tomography (CT), appear to be invaluable tools to ... We describe the case of a young patient admitted with heart failure, due to a severely stenotic UAV. Cardiac CT allowed adjusting the imaging plane to the best view in two orthogonal planes to identif... Cardiac CT angiography is crucial to understand the complexity of UAV disease and to differentiate the acommissural from the unicommissural type. Accurate positioning of the imaging plane through the ...

When all computers shut down: the clinical impact of a major cyber-attack on a general hospital.

Healthcare organizations operate in a data-rich environment and depend on digital computerized systems; thus, they may be exposed to cyber threats. Indeed, one of the most vulnerable sectors to hacks ... This study aims to describe a major attack on an entire medical center that resulted in a complete shutdown of all computer systems and to identify the critical actions required to resume regular oper... This study was conducted on a public, general, and acute care referral university teaching hospital.... We report the different recovery measures on various hospital clinical activities and their impact on clinical work.... The system malfunction of hospital computers did not reduce the number of heart catheterizations, births, or outpatient clinic visits. However, a sharp drop in surgical activities, emergency room visi... The risk of ransomware cyberattacks is growing. Healthcare systems at all levels of the hospital should be aware of this threat and implement protocols should this catastrophic event occur. Careful ev...

Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches.

The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host in... Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computa... Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never test... The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies....